Browse by UCL people
Group by: Type | Date
Jump to: Article
Number of items: 91.
Article
Abou-Alfa, GK;
Macarulla, T;
Javle, MM;
Kelley, RK;
Lubner, SJ;
Adeva, J;
Cleary, JM;
... Zhu, AX; + view all
(2020)
Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.
The Lancet Oncology
, 21
(6)
pp. 796-807.
10.1016/S1470-2045(20)30157-1.
|
|
Agbamu, DA;
Day, N;
Walsh, CJ;
Hendrickse, CW;
Langman, G;
Pallan, A;
Lowe, A;
... Lees, N; + view all
(2012)
Feasibility of preoperative chemotherapy for locally advanced, operable colon cancer: The pilot phase of a randomised controlled trial.
The Lancet Oncology
, 13
(11)
1152 - 1160.
10.1016/S1470-2045(12)70348-0.
|
 |
|
Andre, T;
Boni, C;
Mounedji-Boudiaf, L;
Navarro, M;
Tabernero, J;
Hickish, T;
Topham, C;
... de Gramont, A; + view all
(2004)
Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.
NEW ENGLAND JOURNAL OF MEDICINE
, 350
(23)
pp. 2343-2351.
10.1056/NEJMoa032709.
|
|
|
Au, L;
Hatipoglu, E;
Robert de Massy, M;
Litchfield, K;
Beattie, G;
Rowan, A;
Schnidrig, D;
... TRACERx Renal Consortium; + view all
(2021)
Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma.
Cancer Cell
, 39
pp. 1497-1518.
10.1016/j.ccell.2021.10.001.
|
 |
|
Backen, AC;
Lopes, A;
Wasan, H;
Palmer, DH;
Duggan, M;
Cunningham, D;
Anthoney, A;
... Valle, JW; + view all
(2018)
Circulating biomarkers during treatment in patients with advanced biliary tract cancer receiving cediranib in the UK ABC-03 trial.
British Journal of Cancer
, 119
pp. 27-35.
10.1038/s41416-018-0132-8.
|
|
|
Banales, JM;
Marin, JJG;
Lamarca, A;
Rodrigues, PM;
Khan, SA;
Roberts, LR;
Cardinale, V;
... Gores, GJ; + view all
(2020)
Cholangiocarcinoma 2020: the next horizon in mechanisms and management.
Nature Reviews Gastroenterology & Hepatology
10.1038/s41575-020-0310-z.
(In press).
|
|
|
Barry, A;
Apisarnthanarax, S;
O'Kane, GM;
Sapisochin, G;
Beecroft, R;
Salem, R;
Yoon, SM;
... Hawkins, MA; + view all
(2020)
Management of primary hepatic malignancies during the COVID-19 pandemic: recommendations for risk mitigation from a multidisciplinary perspective.
The Lancet Gastroenterology & Hepatology
10.1016/S2468-1253(20)30182-5.
(In press).
|
|
Bekaii-Saab, TS;
Bridgewater, J;
Normanno, N;
(2021)
Practical considerations in screening for genetic alterations in cholangiocarcinoma.
Annals of Oncology
10.1016/j.annonc.2021.04.012.
(In press).
|
|
|
Bekaii-Saab, TS;
Valle, JW;
Cutsem, EV;
Rimassa, L;
Furuse, J;
Ioka, T;
Melisi, D;
... Vogel, A; + view all
(2020)
FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements.
Future Oncology
10.2217/fon-2020-0429.
(In press).
|
|
|
Benson, AB;
Kiss, I;
Bridgewater, J;
Eskens, FALM;
Sasse, C;
Vossen, S;
Chen, J;
... Krivoshik, A; + view all
(2016)
BATON-CRC: A Phase II Randomized Trial Comparing Tivozanib Plus mFOLFOX6 with Bevacizumab Plus mFOLFOX6 in Stage IV Metastatic Colorectal Cancer.
Clinical Cancer Research
, 22
(20)
pp. 5058-5067.
10.1158/1078-0432.CCR-15-3117.
|
|
Bridgewater, John;
Fletcher, Peter;
Palmer, Daniel H;
Malik, Hassan Z;
Prasad, Raj;
Mirza, Darius;
Anthony, Alan;
... BILCAP study group, .; + view all
(2022)
Long-Term Outcomes and Exploratory Analyses of the Randomized Phase III BILCAP Study.
Journal of Clinical Oncology
, 40
(18)
pp. 2048-2057.
10.1200/JCO.21.02568.
|
|
Bridgewater, John;
Jiao, Xiaolong;
Parimi, Mounika;
Flach, Clare;
Stratford, Jeran;
Kamburov, Atanas;
Schmitz, Arndt A;
... Bazhenova, Lyudmila; + view all
(2022)
Prognosis and oncogenomic profiling of patients with tropomyosin receptor kinase fusion cancer in the 100,000 genomes project.
Cancer Treatment and Research Communications
, 33
, Article 100623. 10.1016/j.ctarc.2022.100623.
|
|
Bridgewater, J;
(2019)
Systemic treatment of biliary tract cancer: now we have evidence.
Annals of Oncology
, 30
(12)
pp. 1851-1852.
10.1093/annonc/mdz441.
|
|
Bridgewater, J;
Lopes, A;
Beare, S;
Duggan, M;
Lee, D;
Ricamara, M;
McEntee, D;
... Valle, JW; + view all
(2016)
A phase 1b study of Selumetinib in combination with Cisplatin and Gemcitabine in advanced or metastatic biliary tract cancer: the ABC-04 study.
BMC Cancer
, 16
(1)
p. 153.
10.1186/s12885-016-2174-8.
|
|
|
Bridgewater, JA;
Pugh, SA;
Maishman, T;
Eminton, Z;
Mellor, J;
Whitehead, A;
Stanton, L;
... New EPOC investigators; + view all
(2020)
Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis (New EPOC): long-term results of a multicentre, randomised, controlled, phase 3 trial.
The Lancet Oncology
, 21
(3)
pp. 398-411.
10.1016/S1470-2045(19)30798-3.
|
|
|
Calvisi, DF;
Boulter, L;
Vaquero, J;
Saborowski, A;
Fabris, L;
Rodrigues, PM;
Coulouarn, C;
... Saito, Y; + view all
(2023)
Criteria for preclinical models of cholangiocarcinoma: scientific and medical relevance.
Nature Reviews Gastroenterology and Hepatology
, 20
pp. 462-480.
10.1038/s41575-022-00739-y.
|
|
Castet, Florian;
Fabregat-Franco, Carles;
Bridgewater, John;
Kim, Jin Won;
Rimini, Margherita;
La Casta, Adelaida;
Lamarca, Angela;
... DURVABTC Group, Group; + view all
(2025)
Association of candidate surrogate endpoints with overall survival in advanced biliary tract cancer.
Journal of Hepatology
10.1016/j.jhep.2025.05.020.
(In press).
|
|
Chau, I;
Joulain, F;
Iqbal, SU;
Bridgewater, J;
(2014)
A VELOUR post hoc subset analysis: prognostic groups and treatment outcomes in patients with metastatic colorectal cancer treated with aflibercept and FOLFIRI.
BMC Cancer
, 14
, Article 605. 10.1186/1471-2407-14-605.
|
  |
|
Corrie, PG;
Qian, W;
Basu, B;
Valle, JW;
Falk, S;
Lwuji, C;
Wasan, H;
... Jodrell, DI; + view all
(2020)
Scheduling nab-paclitaxel combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma.
British Journal of Cancer
10.1038/s41416-020-0846-2.
|
|
|
Cox, S;
Hurt, C;
Grenader, T;
Mukherjee, S;
Bridgewater, J;
Crosby, T;
(2017)
The prognostic value of derived neutrophil to lymphocyte ratio in oesophageal cancer treated with definitive chemoradiotherapy.
Radiotherapy and Oncology
, 125
(1)
pp. 154-159.
10.1016/j.radonc.2017.08.023.
|
|
Crolley, VE;
Hanna, D;
Joharatnam-Hogan, N;
Chopra, N;
Bamac, E;
Desai, M;
Lam, YC;
... Khan, K; + view all
(2020)
COVID-19 in cancer patients on systemic anti-cancer therapies: outcomes from the CAPITOL (COVID-19 Cancer PatIenT Outcomes in North London) cohort study.
Therapeutic Advances in Medical Oncology
, 12
pp. 1-14.
10.1177/1758835920971147.
|
|
|
Crosby, T;
Hurt, CN;
Falk, S;
Gollins, S;
Staffurth, J;
Ray, R;
Bridgewater, JA;
... Mukherjee, S; + view all
(2017)
Long-term results and recurrence patterns from SCOPE-1: a phase II/III randomised trial of definitive chemoradiotherapy +/- cetuximab in oesophageal cancer.
British Journal of Cancer
, 116
pp. 709-716.
10.1038/bjc.2017.21.
|
|
|
Doki, Yuichiro;
Ajani, Jaffer A;
Kato, Ken;
Xu, Jianming;
Wyrwicz, Lucjan;
Motoyama, Satoru;
Ogata, Takashi;
... CheckMate 648 Trial Investigators; + view all
(2022)
Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma.
New England Journal of Medicine
, 386
(5)
pp. 449-462.
10.1056/NEJMoa2111380.
|
|
Edeline, Julien;
Bridgewater, John;
Campillo-Gimenez, Boris;
Neveu, Estelle;
Phelip, Jean-Marc;
Neuzillet, Cindy;
Boudjema, Karim;
... Lamarca, Angela; + view all
(2024)
Chemotherapy with or without selective internal radiation therapy for intrahepatic cholangiocarcinoma: Data from clinical trials.
Hepatology
, 79
(1)
pp. 96-106.
10.1097/HEP.0000000000000544.
|
|
Evans, REC;
Taylor, SA;
Kalasthry, J;
Sakai, NS;
Miles, A;
Streamline investigators;
(2019)
Patient deprivation and perceived scan burden negatively impact the quality of whole-body MRI.
Clinical Radiology
10.1016/j.crad.2019.10.019.
(In press).
|
|
|
Glynne-Jones, R;
Hall, MR;
Lopes, A;
Pearce, S;
Goh, V;
Bosompem, S;
Bridgewater, J;
... Harrison, M; + view all
(2018)
BACCHUS: A randomised non-comparative phase II study of neoadjuvant chemotherapy (NACT) in patients with locally advanced rectal cancer (LARC).
Heliyon
, 4
(9)
, Article e00804. 10.1016/j.heliyon.2018.e00804.
|
|
|
Gootjes, EC;
Bakkerus, L;
ten Tije, AJ;
Witteveen, PO;
Buffart, TE;
Bridgewater, JA;
Primrose, JN;
... Verheul, HMW; + view all
(2018)
The value of tumour debulking for patients with extensive multi-organ metastatic colorectal cancer.
European Journal of Cancer Prevention
, 103
pp. 160-164.
10.1016/j.ejca.2018.07.012.
|
|
Goyal, L;
Kongpetch, S;
Crolley, VE;
Bridgewater, J;
(2021)
Targeting FGFR inhibition in cholangiocarcinoma.
Cancer Treatment Reviews
, 95
, Article 102170. 10.1016/j.ctrv.2021.102170.
|
|
Goyal, Lipika;
Meric-Bernstam, Funda;
Hollebecque, Antoine;
Valle, Juan W;
Morizane, Chigusa;
Karasic, Thomas B;
Abrams, Thomas A;
... FOENIX-CCA2 Study Investigators; + view all
(2023)
Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma.
New England Journal of Medicine
, 388
(3)
pp. 228-239.
10.1056/NEJMoa2206834.
|
|
Harding, James J;
Fan, Jia;
Oh, Do-Youn;
Choi, Hye Jin;
Kim, Jin Won;
Chang, Heung-Moon;
Bao, Lequn;
... HERIZON-BTC-01 study group; + view all
(2023)
Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study.
The Lancet Oncology
, 24
(7)
pp. 772-782.
10.1016/S1470-2045(23)00242-5.
|
|
Heide, Timon;
Househam, Jacob;
Cresswell, George D;
Spiteri, Inmaculada;
Lynn, Claire;
Mossner, Maximilian;
Kimberley, Chris;
... Sottoriva, Andrea; + view all
(2022)
The co-evolution of the genome and epigenome in colorectal cancer.
Nature
10.1038/s41586-022-05202-1.
(In press).
|
|
Hill, AG;
Findlay, M;
Burge, M;
Jackson, C;
García Alfonso, P;
Samuel, L;
Ganju, V;
... Tabernero, J; + view all
(2018)
Phase II study of the dual EGFR/HER3 inhibitor duligotuzumab (MEHD7945A) vs. cetuximab in combination with FOLFIRI in RAS wild-type metastatic colorectal cancer.
Clinical Cancer Research
, 42
(10)
pp. 2276-2284.
10.1158/1078-0432.CCR-17-0646.
|
|
Hoffman, HI;
Guo, JA;
Hawkins, MA;
Bridgewater, JA;
Wo, JY;
Hong, TS;
Hwang, WL;
(2020)
Silver Linings: An Opportunity to Improve Clinical Paradigms After the COVID-19 Pandemic.
JCO Oncology Practice
10.1200/OP.20.00335.
(In press).
|
|
Househam, Jacob;
Heide, Timon;
Cresswell, George D;
Spiteri, Inmaculada;
Kimberley, Chris;
Zapata, Luis;
Lynn, Claire;
... Graham, Trevor A; + view all
(2022)
Phenotypic plasticity and genetic control in colorectal cancer evolution.
Nature
10.1038/s41586-022-05311-x.
|
|
Iveson, T;
Boyd, KA;
Kerr, RS;
Robles-Zurita, J;
Saunders, MP;
Briggs, AH;
Cassidy, J;
... Paul, J; + view all
(2019)
3-month versus 6-month adjuvant chemotherapy for patients with high-risk stage II and III colorectal cancer: 3-year follow-up of the SCOT non-inferiority RCT.
Health Technology Assessment
, 23
(64)
pp. 1-88.
10.3310/hta23640.
|
|
|
Iveson, TJ;
Kerr, RS;
Saunders, MP;
Cassidy, J;
Henrik Hollander, N;
Tabernero, J;
Haydon, A;
... Paul, J; + view all
(2018)
3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial.
Lancet Oncology
, 19
(4)
pp. 562-578.
10.1016/S1470-2045(18)30093-7.
|
|
|
Iyer, RV;
Acquisto, SG;
Bridgewater, JA;
Choti, MA;
Hong, TS;
Kis, B;
Mead, PA;
... Valle, JW; + view all
(2020)
Guidelines for Management of Urgent Symptoms in Patients with Cholangiocarcinoma and Biliary Stents or Catheters Using the Modified RAND/UCLA Delphi Process.
Cancers
, 12
(9)
, Article 2375. 10.3390/cancers12092375.
|
|
|
Joharatnam-Hogan, N;
Cafferty, F;
Hubner, R;
Swinson, D;
Sothi, S;
Gupta, K;
Falk, S;
... Add-Aspirin Trial Management Group; + view all
(2019)
Aspirin as an adjuvant treatment for cancer: feasibility results from the Add-Aspirin randomised trial.
The Lancet Gastroenterology & Hepatology
, 4
(11)
pp. 854-862.
10.1016/S2468-1253(19)30289-4.
|
|
Joharatnam-Hogan, N;
Hochhauser, D;
Shiu, K-K;
Rush, H;
Crolley, V;
Wilson, W;
Sharma, A;
... Khan, K; + view all
(2020)
Outcomes of the 2019 novel coronavirus in patients with or without a history of cancer: a multi-centre North London experience.
Therapeutic Advances in Medical Oncology
pp. 1-9.
10.1177/1758835920956803.
|
|
Joharatnam-Hogan, N;
Wilson, W;
Shiu, KK;
Fusai, GK;
Davidson, B;
Hochhauser, D;
Bridgewater, J;
(2020)
Multimodal Treatment in Metastatic Colorectal Cancer (mCRC) Improves Outcomes—The University College London Hospital (UCLH) Experience.
Cancers
, 12
(12)
, Article 3545. 10.3390/cancers12123545.
|
|
|
Jones, CM;
Radhakrishna, G;
Aitken, K;
Bridgewater, J;
Corrie, P;
Eatock, M;
Goody, R;
... Mukherjee, S; + view all
(2020)
Considerations for the treatment of pancreatic cancer during the COVID-19 pandemic: the UK consensus position.
British Journal of Cancer
, 123
pp. 709-713.
10.1038/s41416-020-0980-x.
|
|
Katipally, Rohan R;
Martinez, Carlos A;
Pugh, Siân A;
Bridgewater, John A;
Primrose, John N;
Domingo, Enric;
Maughan, Timothy S;
... with the S:CORT Consortium; + view all
(2023)
Integrated Clinical-Molecular Classification of Colorectal Liver Metastases: A Biomarker Analysis of the Phase 3 New EPOC Randomized Clinical Trial.
JAMA Oncology
10.1001/jamaoncol.2023.2535.
(In press).
|
|
Kefas, Joanna;
Bridgewater, John;
Vogel, Arndt;
Stein, Alexander;
Primrose, John;
(2023)
Adjuvant therapy of biliary tract cancers.
Therapeutic Advances in Medical Oncology
, 15
10.1177/17588359231163785.
|
|
Kelley, RK;
Bridgewater, J;
Gores, GJ;
Zhu, AX;
(2020)
Systemic therapies for intrahepatic cholangiocarcinoma.
Journal of Hepatology
, 72
(2)
pp. 353-363.
10.1016/j.jhep.2019.10.009.
|
|
Laethem, J-LV;
Riess, H;
Jassem, J;
Haas, M;
Martens, UM;
Weekes, C;
Peeters, M;
... Childs, BH; + view all
(2016)
Phase I/II Study of Refametinib (BAY 86-9766) in Combination with Gemcitabine in Advanced Pancreatic cancer.
Targeted Oncology
, 12
(1)
pp. 97-109.
10.1007/s11523-016-0469-y.
|
|
|
Lamarca, Angela;
Ross, Paul;
Wasan, Harpreet S;
Hubner, Richard A;
McNamara, Mairéad G;
Lopes, Andre;
Palmer, Daniel;
... Bridgewater, John; + view all
(2025)
Advanced Ampullary Cancer: post-hoc analysis of the ABC-01, -02 and -03 clinical trials.
Oncologist
10.1093/oncolo/oyaf399.
(In press).
|
|
|
Lamarca, A;
Edeline, J;
McNamara, MG;
Hubner, RA;
Nagino, M;
Bridgewater, J;
Primrose, J;
(2020)
Current standards and future perspectives in adjuvant treatment for biliary tract cancers.
Cancer Treatment Reviews
, 84
, Article 101936. 10.1016/j.ctrv.2019.101936.
|
|
Lamarca, A;
Palmer, DH;
Wasan, HS;
Ross, PJ;
Ma, YT;
Arora, A;
Falk, S;
... Advanced Biliary Cancer Working Group; + view all
(2021)
Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial.
The Lancet Oncology
10.1016/S1470-2045(21)00027-9.
(In press).
|
|
|
Lamarca, A;
Ross, P;
Wasan, HS;
Hubner, RA;
McNamara, MG;
Lopes, A;
Manoharan, P;
... Valle, JW; + view all
Advanced intrahepatic cholangiocarcinoma: post-hoc analysis of the ABC-01, -02 and -03 clinical trials.
Journal of the National Cancer Institute
10.1093/jnci/djz071.
(In press).
|
|
|
Litchfield, K;
Stanislaw, S;
Spain, L;
Gallegos, LL;
Rowan, A;
Schnidrig, D;
Rosenbaum, H;
... Turajlic, S; + view all
(2020)
Representative Sequencing: Unbiased Sampling of Solid Tumor Tissue.
Cell Reports
, 31
(5)
p. 107550.
10.1016/j.celrep.2020.107550.
|
|
Macias, Rocio IR;
Cardinale, Vincenzo;
Kendall, Timothy J;
Avila, Matias A;
Guido, Maria;
Coulouarn, Cedric;
Braconi, Chiara;
... Carpino, Guido; + view all
(2022)
Clinical relevance of biomarkers in cholangiocarcinoma: critical revision and future directions.
Gut
10.1136/gutjnl-2022-327099.
(In press).
|
|
Mahmood, Umair;
Muhamad Faizul, Elisya;
Howlett, Sarah;
Amin, Zahir;
Hochhauser, Daniel;
Shiu, Kai-Keen;
Bridgewater, John;
(2024)
Comprehensive Examination of Cholangiocarcinoma Patients Treated with Novel Targeted Therapies after Extended Molecular Profiling on Liquid Biopsies.
Cancers
, 16
(4)
, Article 697. 10.3390/cancers16040697.
|
|
Marin, JJG;
Prete, MG;
Lamarca, A;
Tavolari, S;
Landa-Magdalena, A;
Brandi, G;
Segatto, O;
... Braconi, C; + view all
(2020)
Current and novel therapeutic opportunities for systemic therapy in biliary cancer.
British Journal of Cancer
, 123
pp. 1047-1059.
10.1038/s41416-020-0987-3.
|
|
McNamara, Mairéad G;
Bridgewater, John;
Goyal, Lipika;
Jacobs, Timothy;
Wagner, Anna D;
Goldstein, David;
Shroff, Rachna;
... Valle, Juan; + view all
(2022)
What is the gender representation in authorship in later phase systemic clinical trials in biliary tract cancer (BTC)? - a retrospective review of the published literature.
BMJ Open
, 12
(10)
, Article e064954. 10.1136/bmjopen-2022-064954.
|
|
McNamara, MG;
Bridgewater, J;
Palmer, DH;
Faluyi, O;
Wasan, H;
Patel, A;
Ryder, WD;
... Valle, JW; + view all
(2021)
A Phase Ib Study of NUC-1031 in Combination with Cisplatin for the First-Line Treatment of Patients with Advanced Biliary Tract Cancer (ABC-08).
The Oncologist
, 26
(4)
e669-e678.
10.1002/onco.13598.
|
|
McNamara, MG;
Bridgewater, J;
Lopes, A;
Wasan, H;
Malka, D;
Jensen, LH;
Okusaka, T;
... Valle, JW; + view all
(2017)
Systemic therapy in younger and elderly patients with advanced biliary cancer: sub-analysis of ABC-02 and twelve other prospective trials.
BMC Cancer
, 17
, Article 262. 10.1186/s12885-017-3266-9.
|
|
|
McNamara, MG;
Lopes, A;
Wasan, H;
Malka, D;
Goldstein, D;
Shannon, J;
Okusaka, T;
... Valle, JW; + view all
(2020)
Landmark survival analysis and impact of anatomic origin in prospective clinical trials of biliary tract cancer.
Journal of Hepatology
, 73
(5)
pp. 1109-1117.
10.1016/j.jhep.2020.05.014.
|
|
Meric-Bernstam, F;
Bahleda, R;
Hierro, C;
Sanson, M;
Bridgewater, J;
Arkenau, H-T;
Tran, B;
... Goyal, L; + view all
(2021)
Futibatinib, an irreversible FGFR1-4 inhibitor, in patients with advanced solid tumors harboring FGF/FGFR aberrations: a phase I dose-expansion study.
Cancer Discovery
10.1158/2159-8290.CD-21-0697.
(In press).
|
|
|
Miles, A;
Evans, RE;
Halligan, S;
Beare, S;
Bridgewater, J;
Goh, V;
Janes, SM;
... STREAMLINE investigators; + view all
(2020)
Predictors of patient preference for either whole body magnetic resonance imaging (WB-MRI) or CT/ PET-CT for staging colorectal or lung cancer.
Journal of Medical Imaging and Radiation Oncology
10.1111/1754-9485.13038.
(In press).
|
|
|
Miles, A;
Taylor, SA;
Evans, REC;
Halligan, S;
Beare, S;
Bridgewater, J;
Goh, V;
... Yu, D; + view all
(2019)
Patient preferences for whole-body MRI or conventional staging pathways in lung and colorectal cancer: a discrete choice experiment.
European Radiology
, 29
(7)
pp. 3889-3900.
10.1007/s00330-019-06153-4.
|
|
|
Mukherjee, Somnath;
Qi, Cathy;
Shaw, Rachel;
Jones, Christopher M;
Bridgewater, John A;
Radhakrishna, Ganesh;
Patel, Neel;
... Corrie, Pippa; + view all
(2024)
Standard or high dose chemoradiotherapy, with or without the protease inhibitor nelfinavir, in patients with locally advanced pancreatic cancer: The phase 1/randomised phase 2 SCALOP-2 trial.
European Journal of Cancer
, 209
, Article 114236. 10.1016/j.ejca.2024.114236.
|
 |
|
Muñoz-Martínez, S;
Sapena, V;
Forner, A;
Nault, J-C;
Sapisochin, G;
Rimassa, L;
Sangro, B;
... Reig, M; + view all
(2021)
Assessing the impact of COVID-19 on liver cancer management (CERO-19).
JHEP Reports
, Article 100260. 10.1016/j.jhepr.2021.100260.
(In press).
|
|
|
Nooijen, Lynn E;
van der Snee, Lizzel;
Ten Haaft, Britte;
Kazemier, Geert;
Klümpen, Heinz-Josef;
Bridgewater, John;
Primrose, John;
(2023)
A critical appraisal of the potential benefit of post-operative structured follow-up after resection for biliary tract cancer.
HPB
10.1016/j.hpb.2023.10.004.
(In press).
|
|
|
O'Rourke, Colm J;
Salati, Massimiliano;
Rae, Colin;
Carpino, Guido;
Leslie, Holly;
Pea, Antonio;
Prete, Maria G;
... Braconi, Chiara; + view all
(2023)
Molecular portraits of patients with intrahepatic cholangiocarcinoma who diverge as rapid progressors or long survivors on chemotherapy.
Gut
10.1136/gutjnl-2023-330748.
(In press).
|
|
|
Pereira, SP;
Jitlal, M;
Duggan, M;
Lawrie, E;
Beare, S;
O'Donoghue, P;
Wasan, HS;
... PHOTOSTENT-02 investigators, .; + view all
(2018)
PHOTOSTENT-02: porfimer sodium photodynamic therapy plus stenting versus stenting alone in patients with locally advanced or metastatic biliary tract cancer.
ESMO Open
, 3
(5)
, Article e000379. 10.1136/esmoopen-2018-000379.
|
|
|
Primrose, JN;
Fox, RP;
Palmer, DH;
Malik, HZ;
Prasad, R;
Mirza, D;
Anthony, A;
... Bridgewater, J; + view all
(2019)
Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study.
Lancet Oncology
, 20
(5)
pp. 663-673.
10.1016/S1470-2045(18)30915-X.
|
|
Pugh, S;
Thiébaut, R;
Bridgewater, J;
Grisoni, ML;
Moutasim, K;
Rousseau, F;
Thomas, GJ;
... Laurent-Puig, P; + view all
(2017)
Association between miR-31-3p expression and cetuximab efficacy in patients with KRAS wild-type metastatic colorectal cancer: A post-hoc analysis of the New EPOC trial.
Oncotarget
, 8
(55)
pp. 93856-93866.
10.18632/oncotarget.21291.
|
|
|
Pugh, SA;
Bowers, M;
Ball, A;
Falk, S;
Finch-Jones, M;
Valle, JW;
O'Reilly, DA;
... Primrose, JN; + view all
(2016)
Patterns of progression, treatment of progressive disease and post-progression survival in the New EPOC study.
British Journal of Cancer
, 115
(4)
pp. 420-424.
10.1038/bjc.2016.208.
|
|
|
Rao, S;
Sclafani, F;
Eng, C;
Adams, RA;
Guren, MG;
Sebag-Montefiore, D;
Benson, A;
... Cunningham, D; + view all
(2020)
International Rare Cancers Initiative Multicenter Randomized Phase II Trial of Cisplatin and Fluorouracil Versus Carboplatin and Paclitaxel in Advanced Anal Cancer: InterAAct.
Journal of Clinical Oncology
, 38
(22)
pp. 2510-2518.
10.1200/JCO.19.03266.
|
|
Robles-Zurita, J;
Boyd, KA;
Briggs, AH;
Iveson, T;
Kerr, RS;
Saunders, MP;
Cassidy, J;
... Paul, J; + view all
(2018)
SCOT: a comparison of cost-effectiveness from a large randomised phase III trial of two durations of adjuvant Oxaliplatin combination chemotherapy for colorectal cancer.
British Journal of Cancer
, 119
pp. 1332-1338.
10.1038/s41416-018-0319-z.
|
|
|
Rushbrook, Simon M;
Kendall, Timothy James;
Zen, Yoh;
Albazaz, Raneem;
Manoharan, Prakash;
Pereira, Stephen P;
Sturgess, Richard;
... Khan, Shahid A; + view all
(2023)
British Society of Gastroenterology guidelines for the diagnosis and management of cholangiocarcinoma.
Gut
10.1136/gutjnl-2023-330029.
(In press).
|
|
|
Selvadurai, S;
Mann, K;
Mithra, S;
Bridgewater, J;
Malik, H;
Khan, SA;
(2021)
Cholangiocarcinoma miscoding in hepatobiliary centres.
European Journal of Surgical Oncology
, 47
(3)
pp. 635-639.
10.1016/j.ejso.2020.09.039.
|
|
Singer, R;
Campbell, P;
Fernandes, C;
Statham, P;
Hochhauser, D;
Bridgewater, J;
(2017)
Time to endoscopic intervention in patients with upper gastrointestinal patients can be improved with pathway provision.
BMC Cancer
, 17
, Article 365. 10.1186/s12885-017-3335-0.
|
|
|
Spurr, Liam F;
Martinez, Carlos A;
Katipally, Rohan R;
Iyer, Soumya C;
Pugh, Sian A;
Bridgewater, John A;
Primrose, John N;
... Pitroda, Sean P; + view all
(2022)
A proliferative subtype of colorectal liver metastases exhibits hypersensitivity to cytotoxic chemotherapy.
npj Precision Oncology
, 6
, Article 72. 10.1038/s41698-022-00318-z.
|
|
Strauss, VY;
Shaw, R;
Virdee, PS;
Hurt, CN;
Ward, E;
Tranter, B;
Patel, N;
... Mukherjee, S; + view all
(2019)
Study protocol: a multi-centre randomised study of induction chemotherapy followed by capecitabine ± nelfinavir with high- or standard-dose radiotherapy for locally advanced pancreatic cancer (SCALOP-2).
BMC Cancer
, 19
, Article 121. 10.1186/s12885-019-5307-z.
|
|
|
Suzuki, E;
Bridgewater, J;
(2019)
Adjuvant therapy for resected gallbladder cancer.
Chinese Clinical Oncology
, 8
(4)
, Article 39. 10.21037/cco.2019.07.02.
|
|
|
Taieb, Julien;
Seufferlein, Thomas;
Reni, Michele;
Palmer, Daniel H;
Bridgewater, John A;
Cubillo, Antonio;
Prager, Gerald W;
... Macarulla, Teresa; + view all
(2023)
Treatment sequences and prognostic/predictive factors in metastatic pancreatic ductal adenocarcinoma: univariate and multivariate analyses of a real-world study in Europe.
BMC Cancer
, 23
(1)
, Article 877. 10.1186/s12885-023-11377-1.
|
|
Taieb, J;
Balogoun, R;
Le Malicot, K;
Tabernero, J;
Mini, E;
Folprecht, G;
Van Laethem, JL;
... PETACC8 investigators, .; + view all
(2016)
Adjuvant FOLFOX +/- cetuximab in full RAS and BRAF wildtype stage III colon cancer patients.
Annals of Oncology
10.1093/annonc/mdw687.
(In press).
|
|
Taieb, J;
Kourie, HR;
Emile, J-F;
Le Malicot, K;
Balogoun, R;
Tabernero, J;
Mini, E;
... Pan-European Trials in Alimentary Tract Cancer (PETACC)-8 Invest; + view all
(2017)
Association of Prognostic Value of Primary Tumor Location in Stage III Colon Cancer With RAS and BRAF Mutational Status.
JAMA Oncology
10.1001/jamaoncol.2017.3695.
(In press).
|
|
Taylor, SA;
Mallett, S;
Ball, S;
Beare, S;
Bhatnagar, G;
Bhowmik, A;
Boavida, P;
... Streamline investigators; + view all
(2019)
Diagnostic accuracy of whole-body MRI versus standard imaging pathways for metastatic disease in newly diagnosed non-small-cell lung cancer: the prospective Streamline L trial.
Lancet Respiratory Medicine
10.1016/S2213-2600(19)30090-6.
(In press).
|
|
|
Taylor, SA;
Mallett, S;
Beare, S;
Bhatnagar, G;
Blunt, D;
Boavida, P;
Bridgewater, J;
... Streamline investigators; + view all
(2019)
Diagnostic accuracy of whole-body MRI versus standard imaging pathways for metastatic disease in newly diagnosed colorectal cancer: the prospective Streamline C trial.
The Lancet Gastroenterology & Hepatology
, 4
(7)
pp. 529-537.
10.1016/S2468-1253(19)30056-1.
|
|
|
Taylor, SA;
Mallett, S;
Bhatnagar, G;
Morris, S;
Quinn, L;
Tomini, F;
Miles, A;
... Halligan, S; + view all
(2019)
Magnetic resonance enterography compared with ultrasonography in newly diagnosed and relapsing Crohn's disease patients: the METRIC diagnostic accuracy study.
Health Technol Assess
, 23
(42)
pp. 1-161.
10.3310/hta23420.
|
|
|
Taylor, SA;
Mallett, S;
Miles, A;
Beare, S;
Bhatnagar, G;
Bridgewater, J;
Glynne-Jones, R;
... Halligan, S; + view all
(2017)
Streamlining staging of lung and colorectal cancer with whole body MRI; study protocols for two multicentre, non-randomised, single-arm, prospective diagnostic accuracy studies (Streamline C and Streamline L).
BMC Cancer
, 17
, Article 299. 10.1186/s12885-017-3281-x.
|
|
Taylor, SA;
Mallett, S;
Miles, A;
Morris, S;
Quinn, L;
Clarke, CS;
Beare, S;
... Halligan, S; + view all
(2019)
Whole-body MRI compared with standard pathways for staging metastatic disease in lung and colorectal cancer: the Streamline diagnostic accuracy studies.
Health Technology Assessment
, 23
(66)
10.3310/hta23660.
|
|
|
Valle, JW;
Wasan, H;
Lopes, A;
Backen, AC;
Palmer, DH;
Morris, K;
Duggan, M;
... Bridgewater, JA; + view all
(2015)
Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial.
Lancet Oncology
, 16
(8)
pp. 967-978.
10.1016/S1470-2045(15)00139-4.
|
|
Vithayathil, M;
Bridgewater, J;
Khan, SA;
(2021)
Medical therapies for intra-hepatic cholangiocarcinoma.
Journal of Hepatology
, 75
(4)
pp. 981-983.
10.1016/j.jhep.2021.04.004.
|
|
Vogel, A;
Bridgewater, J;
Edeline, J;
Kelley, RK;
Klümpen, HJ;
Malka, D;
Primrose, JN;
... ESMO Guidelines Committee; + view all
(2023)
Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
Annals of Oncology
, 34
(2)
pp. 127-140.
10.1016/j.annonc.2022.10.506.
|
|
Wood, G;
Grenader, T;
Nash, S;
Adams, R;
Kaplan, R;
Fisher, D;
Maughan, T;
(2017)
Derived neutrophil to lymphocyte ratio as a prognostic factor in patients with advanced colorectal cancer according to RAS and BRAF status: a post-hoc analysis of the MRC COIN study.
Anti-Cancer Drugs
, 28
(5)
pp. 546-550.
10.1097/CAD.0000000000000488.
|
|
Yoo, Changhoon;
Javle, Milind M;
Verdaguer Mata, Helena;
de Braud, Filippo;
Trojan, Jörg;
Raoul, Jean-Luc;
Kim, Jin Won;
... Borad, Mitesh J; + view all
(2023)
Phase 2 trial of bintrafusp alfa as second-line therapy for patients with locally advanced/metastatic biliary tract cancers.
Hepatology
, 78
pp. 758-770.
10.1097/HEP.0000000000000365.
|
|
Zhou, C;
O'Connor, J;
Backen, A;
Valle, JW;
Bridgewater, J;
Dive, C;
Jayson, GC;
(2022)
Plasma Tie2 trajectories identify vascular response criteria for VEGF inhibitors across advanced biliary tract, colorectal and ovarian cancers.
ESMO Open
, 7
(2)
, Article 100417. 10.1016/j.esmoop.2022.100417.
|
|
|
Zhu, AX;
Macarulla, T;
Javle, MM;
Kelley, RK;
Lubner, SJ;
Adeva, J;
Cleary, JM;
... Abou-Alfa, GK; + view all
(2021)
Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy Trial.
JAMA Oncology
10.1001/jamaoncol.2021.3836.
(In press).
|
|
